FSP Model Optimization and Scalability for Large Pharma-Focused CRO

Led a transformative restructuring for a mid-sized global CRO shifting from traditional FSO to a hybrid FSO-FSP delivery model amid rising sponsor demand for flexibility. By redesigning resource allocation, embedding high-caliber functional teams (monitoring, data management, biostatistics) within sponsor ecosystems while retaining full-study oversight capabilities, we reduced operational silos, accelerated trial startup by 25%, lowered sponsor change-order frequency by 40%, and positioned the CRO as a preferred partner for complex, multi-protocol pipelines in oncology and rare diseases.